Avelumab binds PD-L1 on tumor cells or APCs, resulting not only in the blocking of the PD-1 pathway in T cells, but also leading to induction of ADCC by NK cells, similarly to the tumor-targeting mAbs discussed earlier (140, 141). The gene discussed is CD274; the disease is neoplasm.